Identification of a Novel Protein Synthesis Inhibitor Active against Gram‐Positive Bacteria

Authors:

Abstract
In an effort to identify novel antibacterial chemotypes, we performed a whole‐cell screen for inhibitors ofStaphylococcus aureusgrowth and pursued those compounds with previously uncharacterized antibacterial activity. This process resulted in the identification of a benzothiazolium salt, ABTZ‐1, that displayed potent antibacterial activity against Gram‐positive pathogens. Several clinically desirable qualities were demonstrated for ABTZ‐1 including potent activity against multidrug‐resistant clinical isolates of methicillin‐resistantS. aureus(MRSA) and vancomycin‐resistant enterococci (VRE), retention of this activity in human serum, and low hemolytic activity. The antibacterial activity of ABTZ‐1 was attributed to its inhibition of bacterial translation, as this compound prevented the incorporation of [35S]methionine intoS. aureusproteins, and ABTZ‐1‐resistant strains were cross‐resistant to known inhibitors of bacterial translation. ABTZ‐1 represents a promising new class of antibacterial agents.

This publication has 37 references indexed in Scilit: